Adverse Childhood ExperiencesNCT07073352
ACEs, SIRT1, and Premature Vascular Aging in Humans
A study testing Nicotinamide Riboside in people with Adverse Childhood Experiences and Endothelial Dysfunction, run by University of Wisconsin, Madison at 2 sites in United States.
Trial summary
Adverse childhood experiences (ACEs) are directly related to cardiovascular morbidity and mortality, and impaired vascular endothelial function (VEF) is an independent predictor of future cardiovascular disease (CVD) risk [1, 2]. Read more about this study
- Who is it for?
- Ages 18 to 30 yearsHealthy volunteers can take part
- Conditions the study is for
- Adverse Childhood Experiences, Endothelial Dysfunction
- What is being tested?
- Nicotinamide Riboside
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 30 participants
- Where
- 2 sitesUnited States
- Study dates
- 27 Mar 2025to 30 Jun 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 30 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- 18 - 30 years
- ACE score of 0 OR ≥4 (Aim 1); ACE score ≥4 (Aim 2)
Who cannot join
- Resting arterial blood pressure >140/90 mmHg
- BMI ≥30 kg/m2 and/or weight unstable (>2.27 kg change) last 6 month
- Cardiovascular, metabolic, or pulmonary disease
- Cardiovascular or metabolic prescription drug use
- Vasoactive antidepressant drug use (SSRIs and clonidine)
- Currently pregnant or breastfeeding
Show all 11Show fewer
- Heavy alcohol consumption (AUDIT screening)
- Use of illicit drugs
- Current tobacco use
- Regular vigorous (>6 MET s) aerobic exercise (>4 bouts/week, >30 min/bout)
- Dietary supplementation with antioxidants or habitual use of NSAIDs
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States2 sites, 1 recruiting
- Completed
Integrative Laboratory of Applied Physiology and Lifestyle Medicine
Iowa City, Iowa, 52242
- Recruiting
Department of Kinesiology, University of Wisconsin
Madison, Wisconsin, 53706
Kylee West, 603-923-1657, kwest8@wisc.edu
About this study
Official title: Adverse Childhood Experiences and Premature Vascular Aging in Humans: The Role of SIRT1
Adverse childhood experiences (ACEs) are directly related to cardiovascular morbidity and mortality, and impaired vascular endothelial function (VEF) is an independent predictor of future cardiovascular disease (CVD) risk [1, 2]. Previous work from our lab (IRB 202010095) and others [3] demonstrates impaired VEF in young adults with prior exposure to ACEs even in the absence of clinical CVD risk factors. Sirtuin 1 (SIRT1) is a class III histone deacetylase (HDAC) that plays a role in regulating vascular homeostasis and reductions in SIRT1 are associated with age-related endothelial dysfunction [4]. We have shown that ACEs-related impairments in VEF are accompanied by reductions in SIRT1 [5]. However, the mechanisms by which ACE exposure promotes VEF remain unknown. The goal of this project is to establish proof of concept that alterations in vascular SIRT1 expression and activity mediate premature vascular aging in individuals with >=4 ACEs compared to those with 0 ACEs and that, because NAD+ is an essential substrate for SIRT1, increasing NAD+ bioavailability will restore VEF in those with >=4 ACEs.
Thus, we will use a robust translational approach coupling in vivo and in vitro measures of endothelial function, inflammation, oxidative stress, and SIRT1 expression and activity in young adults with (n=30-35) versus without (n=30-35) ACE exposure in a cross-sectional study, and during a randomized controlled trial employing a novel 4-week nicotinamide riboside (NR) supplementation approach to increase SIRT1 activity by increasing cellular NAD+ in ACE+ (n=15/group) to accomplish the following specific aims:
Read more
- Determine the mechanisms by which ACE exposure alters the regulation of VEF by SIRT1. We hypothesize that compared to those without ACEs (ACE-), ACE+ will have (H1a) elevated endothelial oxidative stress and inflammation, (H1b) accompanied by reduced endothelial SIRT1 expression and increased p66SHC expression and acetylation of p65 and p53, (H1c) in association with lower VEF.
- Determine how targeting SIRT1 by increasing NAD+ bioavailability affects VEF in young adults with ACEs. We hypothesize that systemic NR supplementation will (H2a) augment cellular SIRT1 activity and (H2b) improve VEF in ACE+.
[1] Felitti, V.J., Anda, R.F., Nordenberg, D., Williamson, D.F., Spitz, A.M., Edwards, V., Koss, M.P., \& Marks, J.S. (1998). Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults: The adverse childhood experiences (ace) study. American Journal of Preventive Medicine, 14(4), 245-258. https://doi.org/10.1016/S0749-3797(98)00017-8. [2] Jenkins, N.D.M., \& Robinson, A.T. (2022). How do adverse childhood experiences get under the skin to promote cardiovascular disease? A focus on vascular health. Function (Oxf), 3(4), zqac032. PMC9279110. 10.1093/function/zqac032. [3] Rodriguez-Miguelez, P., Looney, J., Blackburn, M., Thomas, J., Pollock, J.S., \& Harris, R.A. (2022). The link between childhood adversity and cardiovascular disease risk: Role of cerebral and systemic vasculature. Function. 10.1093/function/zqac029. [4] Thompson, A. M., Wagner, R., \& Rzucidlo, E. M. (2014). Age-related loss of SirT1 expression results in dysregulated human vascular smooth muscle cell function. American Journal of Physiology-Heart and Circulatory Physiology, 307(4), H533-H541. [5] Jenkins, N.D.M., Rogers, E.M., Banks, N.F., Tomko, P.M., Sciarrillo, C.M., Emerson, S.R., Taylor, A., \& Teague, T.K. (2021). Childhood psychosocial stress is linked with impaired vascular endothelial function, lower sirt1, and oxidative stress in young adulthood. Am J Physiol Heart Circ Physiol, 321(3), H532-H541. PMC8461842. 10.1152/ajpheart.00123.2021
- Being tested
- Nicotinamide Riboside, Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nicotinamide RibosideDietary supplement
Participants will consume 1,000 mg of nicotinamide riboside (NR) upon waking and with an evening meal, and complete a daily supplementation log to assist with compliance monitoring. NR is a naturally occurring vitamin B3 derivative readily taken up by cells as a direct NAD+ precursor. Similar NR supplementation protocols are well-tolerated, boost NAD+ concentrations by ~100-140% achieving a steady state within 1-2 weeks, and increase SIRT activity in humans.
PlaceboDietary supplement
Participants will consume 1,000 mg of placebo (microcrystalline cellulose) upon waking and with an evening meal, and complete a daily supplementation log to assist with compliance monitoring.
| Study group | Role | What they receive |
|---|---|---|
| Nicotinamide Riboside | Experimental | 4-weeks of twice daily, oral supplementation (2,000 mg/day) of NR (NIAGEN®
, ChromaDEX, Irvine, CA). Receives: Dietary Supplement: Nicotinamide Riboside |
| Placebo | Placebo comparator | Participants randomized to the control group will consume matched placebo capsules containing microcrystalline cellulose. Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Vascular endothelial function
Vascular endothelial function will be assayed in vivo using the brachial artery flow mediated dilation technique as the relative increase in brachial artery diameter in response to 5-minutes of forearm ischemia (peak - baseline diameter / baseline diameter * 100).
Measured: Before (0 Weeks) and after 4-week supplementation period (4 Weeks)
Secondary outcomes (4)
Endothelial SIRT1 Expression
Total SIRT1 Expression in Primary Endothelial Cells
Measured: Before (0 Weeks) and after 4-week supplementation period (4 Weeks)
Endothelial SIRT1 Activity
Ratio of acetylated:total p53 in Primary Endothelial Cells
Measured: Before (0 Weeks) and after 4-week supplementation period (4 Weeks)
Cellular SIRT1 Activity in PBMCs
Cellular SIRT1 activity from nuclear proteins in isolated peripheral blood mononuclear cells (ab156065).
Measured: Before (0 Weeks) and after 4-week supplementation period (4 Weeks)
Cellular NAD+ metabolites
Semi-targeted high-resolution mass spectrometry will be used to quantify cellular levels of NAD+ and related metabolites, including: nicotinic acid adenine dinucleotide which is a highly sensitive marker of increased NAD+ metabolism via NR supplementation and adenosine diphosphate ribose which is an indicator of NAD+ consuming (SIRT) activity.
Measured: Before (0 Weeks) and after 4-week supplementation period (4 Weeks)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jul 2025
- Study start27 Mar 2025
- Primary completion31 Dec 2026 (estimated)
- Study completion30 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Adverse Childhood ExperiencesStudies of the same condition, open and under way.
- More trials run by University of Wisconsin, MadisonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Wisconsin, Madison
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Nathaniel Jenkins, PhD, Principal investigator, University of Wisconsin, Madison
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07073352
- Sponsor's protocol ID
- 2026-1168
- Other IDs
- UWMSN | SOE | Kinesiology Oper, Protocol Version 8/3/26
- Status last verified
- Aug 2026
- First submitted
- 30 Jun 2025
- Last updated
- 19 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Deidentified data will be made publically available within 1 year of study completion. A study protocol paper will be published in 2026. The informed consent form will also be made publicly available at the award end date.
Study at a glance
From the registry record, last updated by the sponsor on 19 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Adverse Childhood Experiences and Premature Vascular Aging in Humans: The Role of SIRT1
- ClinicalTrials.gov ID
- NCT07073352
- Acronym / sponsor ID
- 2026-1168
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- University of Wisconsin, MadisonUniversity, hospital or other
- Study start
- 27 Mar 2025 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 30 Jun 2027 (estimated)
- First posted
- 18 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Adverse childhood experiences (ACEs) are directly related to cardiovascular morbidity and mortality, and impaired vascular endothelial function (VEF) is an independent predictor of future cardiovascular disease (CVD) risk [1, 2]. Previous work from our lab (IRB 202010095) and others [3] demonstrates impaired VEF in young adults with prior exposure to ACEs even in the absence of clinical CVD risk factors. Sirtuin 1 (SIRT1) is a class III histone deacetylase (HDAC) that plays a role in regulating vascular homeostasis and reductions in SIRT1 are associated with age-related endothelial dysfunction [4]. We have shown that ACEs-related impairments in VEF are accompanied by reductions in SIRT1 [5]. However, the mechanisms by which ACE exposure promotes VEF remain unknown. The goal of this project is to establish proof of concept that alterations in vascular SIRT1 expression and activity mediate premature vascular aging in individuals with >=4 ACEs compared to those with 0 ACEs and that, because NAD+ is an essential substrate for SIRT1, increasing NAD+ bioavailability will restore VEF in those with >=4 ACEs.
Thus, we will use a robust translational approach coupling in vivo and in vitro measures of endothelial function, inflammation, oxidative stress, and SIRT1 expression and activity in young adults with (n=30-35) versus without (n=30-35) ACE exposure in a cross-sectional study, and during a randomized controlled trial employing a novel 4-week nicotinamide riboside (NR) supplementation approach to increase SIRT1 activity by increasing cellular NAD+ in ACE+ (n=15/group) to accomplish the following specific aims:
- Determine the mechanisms by which ACE exposure alters the regulation of VEF by SIRT1. We hypothesize that compared to those without ACEs (ACE-), ACE+ will have (H1a) elevated endothelial oxidative stress and inflammation, (H1b) accompanied by reduced endothelial SIRT1 expression and increased p66SHC expression and acetylation of p65 and p53, (H1c) in association with lower VEF.
- Determine how targeting SIRT1 by increasing NAD+ bioavailability affects VEF in young adults with ACEs. We hypothesize that systemic NR supplementation will (H2a) augment cellular SIRT1 activity and (H2b) improve VEF in ACE+.
[1] Felitti, V.J., Anda, R.F., Nordenberg, D., Williamson, D.F., Spitz, A.M., Edwards, V., Koss, M.P., \& Marks, J.S. (1998). Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults: The adverse childhood experiences (ace) study. American Journal of Preventive Medicine, 14(4), 245-258. https://doi.org/10.1016/S0749-3797(98)00017-8. [2] Jenkins, N.D.M., \& Robinson, A.T. (2022). How do adverse childhood experiences get under the skin to promote cardiovascular disease? A focus on vascular health. Function (Oxf), 3(4), zqac032. PMC9279110. 10.1093/function/zqac032. [3] Rodriguez-Miguelez, P., Looney, J., Blackburn, M., Thomas, J., Pollock, J.S., \& Harris, R.A. (2022). The link between childhood adversity and cardiovascular disease risk: Role of cerebral and systemic vasculature. Function. 10.1093/function/zqac029. [4] Thompson, A. M., Wagner, R., \& Rzucidlo, E. M. (2014). Age-related loss of SirT1 expression results in dysregulated human vascular smooth muscle cell function. American Journal of Physiology-Heart and Circulatory Physiology, 307(4), H533-H541. [5] Jenkins, N.D.M., Rogers, E.M., Banks, N.F., Tomko, P.M., Sciarrillo, C.M., Emerson, S.R., Taylor, A., \& Teague, T.K. (2021). Childhood psychosocial stress is linked with impaired vascular endothelial function, lower sirt1, and oxidative stress in young adulthood. Am J Physiol Heart Circ Physiol, 321(3), H532-H541. PMC8461842. 10.1152/ajpheart.00123.2021
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Nicotinamide Riboside | Experimental | Dietary Supplement: Nicotinamide Riboside4-weeks of twice daily, oral supplementation (2,000 mg/day) of NR (NIAGEN® , ChromaDEX, Irvine, CA). |
| Placebo | Placebo comparator | Dietary Supplement: PlaceboParticipants randomized to the control group will consume matched placebo capsules containing microcrystalline cellulose. |
Who may qualify
- Ages
- 18 to 30 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- 18 - 30 years
- ACE score of 0 OR ≥4 (Aim 1); ACE score ≥4 (Aim 2)
Key exclusion criteria (11 listed)
- Resting arterial blood pressure >140/90 mmHg
- BMI ≥30 kg/m2 and/or weight unstable (>2.27 kg change) last 6 month
- Cardiovascular, metabolic, or pulmonary disease
- Cardiovascular or metabolic prescription drug use
- Vasoactive antidepressant drug use (SSRIs and clonidine)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nicotinamide RibosideParticipants will consume 1,000 mg of nicotinamide riboside (NR) upon waking and with an evening meal, and complete a daily supplementation log to assist with compliance monitoring. NR is a naturally occurring vitamin B3 derivative readily taken up by cells as a direct NAD+ precursor. Similar NR supplementation protocols are well-tolerated, boost NAD+ concentrations by ~100-140% achieving a steady state within 1-2 weeks, and increase SIRT activity in humans. | Dietary supplement | Nicotinamide Riboside |
| PlaceboParticipants will consume 1,000 mg of placebo (microcrystalline cellulose) upon waking and with an evening meal, and complete a daily supplementation log to assist with compliance monitoring. | Dietary supplement | Placebo |
Primary outcome
Vascular endothelial function
Time frame: Before (0 Weeks) and after 4-week supplementation period (4 Weeks)
Vascular endothelial function will be assayed in vivo using the brachial artery flow mediated dilation technique as the relative increase in brachial artery diameter in response to 5-minutes of forearm ischemia (peak - baseline diameter / baseline diameter * 100).
4 secondary outcomes
Endothelial SIRT1 Expression
Time frame: Before (0 Weeks) and after 4-week supplementation period (4 Weeks)
Endothelial SIRT1 Activity
Time frame: Before (0 Weeks) and after 4-week supplementation period (4 Weeks)
Cellular SIRT1 Activity in PBMCs
Time frame: Before (0 Weeks) and after 4-week supplementation period (4 Weeks)
Cellular NAD+ metabolites
Time frame: Before (0 Weeks) and after 4-week supplementation period (4 Weeks)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Aug 2026.
- Individual participant dataSharing planned: Yes. Deidentified data will be made publically available within 1 year of study completion. A study protocol paper will be published in 2026. The informed consent form will also be made publicly available at the award end date.
Related trials for Adverse Childhood Experiences
Not yet recruiting
Preventive and Personalized Digital Emotion Regulation Skills Intervention to Reduce Depression and Anxiety in Youths With Adverse Childhood Experiences
Adverse Childhood Experience, Depression / Major Depressive Disorder
Recruiting
A Pilot Study to Examine the Efficacy of Internet-Delivered Skills Training in Affective and Interpersonal Regulation (i-STAIR) for Individuals With Adverse Childhood Experiences and Subsyndromal Depression
Subthreshold Depression
Active, not recruiting
Resilient Students Training (ReST) : A Pilot RCT
Psychological Wellness
Not yet recruiting
EMI for Reducing Psychological Distress in Young Adults With Multiple ACEs: A RCT Study
Psychological Distress, Adverse Childhood Experience
Not yet recruiting
EMI for Reducing Psychological Distress in Young Adults With Multiple ACEs: A Feasibility Study
Psychological Distress, Adverse Childhood Experience
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Nathaniel Jenkins, PhD principal investigator
University of Wisconsin, Madison
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Nicotinamide Riboside in people with Adverse Childhood Experiences and Endothelial Dysfunction, run by University of Wisconsin, Madison at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 19 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Kylee West (603-923-1657, kwest8@wisc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Vascular endothelial function (time frame: Before (0 Weeks) and after 4-week supplementation period (4 Weeks)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Aug 2026.